Bayer's Kogenate FS gets FDA approval for routine prophylaxis in Hemophilia A patients

Bayer HealthCare has received approval from the US Food and Drug Administration (FDA) for a new indication of its Kogenate FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news